首页 > 最新文献

Journal of Applied Laboratory Medicine最新文献

英文 中文
SARS-CoV-2 Variants May Affect Saliva RT-PCR Assay Sensitivity. SARS-CoV-2 变异可能会影响唾液 RT-PCR 检测的灵敏度。
IF 1.8 Q3 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2024-11-04 DOI: 10.1093/jalm/jfae095
Jason S Chwa, Yunho Shin, Yesun Lee, Thomas Fabrizio, Zion Congrave-Wilson, Wesley A Cheng, Jaycee Jumarang, Minjun Kim, Richard Webby, Jeffrey M Bender, Pia S Pannaraj

Background: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants demonstrate predilection for different regions of the respiratory tract. While saliva-based reverse transcription-polymerase chain reaction (RT-PCR) testing is a convenient, cost-effective alternative to nasopharyngeal swabs (NPS), few studies to date have investigated whether saliva sensitivity differs across variants of concern.

Methods: SARS-CoV-2 RT-PCR was performed on paired NPS and saliva specimens collected from individuals with acute coronavirus disease 2019 (COVID-19) symptoms or exposure to a COVID-19 household contact. Viral genome sequencing of NPS specimens and Los Angeles County surveillance data were used to determine the variant of infection. Saliva sensitivity was calculated using NPS-positive RT-PCR as the reference standard. Factors contributing to the likelihood of saliva SARS-CoV-2 RT-PCR positivity were evaluated with univariate and multivariable analyses.

Results: Between June 2020 and December 2022, 548 saliva samples paired with SARS-CoV-2 positive NPS samples were tested by RT-PCR. Overall, saliva sensitivity for SARS-CoV-2 detection was 61.7% (95% CI, 57.6%-65.7%). Sensitivity was highest with Delta infection (79.6%) compared to pre-Delta (58.5%) and Omicron (61.5%) (P = 0.003 and 0.01, respectively). Saliva sensitivity was higher in symptomatic individuals across all variants compared to asymptomatic cases [pre-Delta 80.6% vs 48.3% (P < 0.001), Delta 100% vs 72.5% (P = 0.03), Omicron 78.7% vs 51.2% (P < 0.001)]. Infection with Delta, symptoms, and high NPS viral load were independently associated with 2.99-, 3.45-, and 4.0-fold higher odds of SARS-CoV-2 detection by saliva-based RT-PCR (P = 0.004, <0.001, and <0.001), respectively.

Conclusions: As new variants emerge, evaluating saliva-based testing approaches may be crucial to ensure effective virus detection.

背景:严重急性呼吸系统综合征冠状病毒-2(SARS-CoV-2)变种显示出对呼吸道不同区域的偏好。虽然基于唾液的反转录聚合酶链反应(RT-PCR)检测是鼻咽拭子(NPS)的一种方便、经济的替代方法,但迄今为止很少有研究调查唾液敏感性在不同变异株之间是否存在差异:方法:对从有 2019 年急性冠状病毒病(COVID-19)症状或接触过 COVID-19 家庭接触者的患者采集的配对鼻咽拭子和唾液标本进行了 SARS-CoV-2 RT-PCR 检测。采用 NPS 标本的病毒基因组测序和洛杉矶县的监测数据来确定感染的变异体。以 NPS 阳性 RT-PCR 作为参考标准计算唾液敏感性。通过单变量和多变量分析评估了导致唾液中 SARS-CoV-2 RT-PCR 阳性的因素:2020年6月至2022年12月期间,对与SARS-CoV-2阳性新农合样本配对的548份唾液样本进行了RT-PCR检测。总体而言,唾液检测 SARS-CoV-2 的灵敏度为 61.7%(95% CI,57.6%-65.7%)。与三角洲前感染(58.5%)和奥米克隆感染(61.5%)相比,三角洲感染的灵敏度最高(79.6%)(P = 0.003 和 0.01)。与无症状病例相比,所有变异体中有症状者的唾液敏感性都更高[Delta 前 80.6% vs 48.3% (P < 0.001),Delta 100% vs 72.5% (P = 0.03),Omicron 78.7% vs 51.2% (P < 0.001)]。感染 Delta、出现症状和 NPS 病毒载量高分别与唾液 RT-PCR 检测出 SARS-CoV-2 的几率增加 2.99 倍、3.45 倍和 4.0 倍有关(P = 0.004,结论:随着新变种的出现,评估基于唾液的检测方法可能对确保有效检测病毒至关重要。
{"title":"SARS-CoV-2 Variants May Affect Saliva RT-PCR Assay Sensitivity.","authors":"Jason S Chwa, Yunho Shin, Yesun Lee, Thomas Fabrizio, Zion Congrave-Wilson, Wesley A Cheng, Jaycee Jumarang, Minjun Kim, Richard Webby, Jeffrey M Bender, Pia S Pannaraj","doi":"10.1093/jalm/jfae095","DOIUrl":"10.1093/jalm/jfae095","url":null,"abstract":"<p><strong>Background: </strong>Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants demonstrate predilection for different regions of the respiratory tract. While saliva-based reverse transcription-polymerase chain reaction (RT-PCR) testing is a convenient, cost-effective alternative to nasopharyngeal swabs (NPS), few studies to date have investigated whether saliva sensitivity differs across variants of concern.</p><p><strong>Methods: </strong>SARS-CoV-2 RT-PCR was performed on paired NPS and saliva specimens collected from individuals with acute coronavirus disease 2019 (COVID-19) symptoms or exposure to a COVID-19 household contact. Viral genome sequencing of NPS specimens and Los Angeles County surveillance data were used to determine the variant of infection. Saliva sensitivity was calculated using NPS-positive RT-PCR as the reference standard. Factors contributing to the likelihood of saliva SARS-CoV-2 RT-PCR positivity were evaluated with univariate and multivariable analyses.</p><p><strong>Results: </strong>Between June 2020 and December 2022, 548 saliva samples paired with SARS-CoV-2 positive NPS samples were tested by RT-PCR. Overall, saliva sensitivity for SARS-CoV-2 detection was 61.7% (95% CI, 57.6%-65.7%). Sensitivity was highest with Delta infection (79.6%) compared to pre-Delta (58.5%) and Omicron (61.5%) (P = 0.003 and 0.01, respectively). Saliva sensitivity was higher in symptomatic individuals across all variants compared to asymptomatic cases [pre-Delta 80.6% vs 48.3% (P < 0.001), Delta 100% vs 72.5% (P = 0.03), Omicron 78.7% vs 51.2% (P < 0.001)]. Infection with Delta, symptoms, and high NPS viral load were independently associated with 2.99-, 3.45-, and 4.0-fold higher odds of SARS-CoV-2 detection by saliva-based RT-PCR (P = 0.004, <0.001, and <0.001), respectively.</p><p><strong>Conclusions: </strong>As new variants emerge, evaluating saliva-based testing approaches may be crucial to ensure effective virus detection.</p>","PeriodicalId":46361,"journal":{"name":"Journal of Applied Laboratory Medicine","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142156309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Applying a DEI-HE Lens to Your Laboratory. 将 DEI-HE 透视镜应用于实验室。
IF 1.8 Q3 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2024-11-04 DOI: 10.1093/jalm/jfae074
Thomas Auen, LaShanta Brice, Aleksei Tikhonov, Jingcai Wang, Ria Fyffe-Freil
{"title":"Applying a DEI-HE Lens to Your Laboratory.","authors":"Thomas Auen, LaShanta Brice, Aleksei Tikhonov, Jingcai Wang, Ria Fyffe-Freil","doi":"10.1093/jalm/jfae074","DOIUrl":"https://doi.org/10.1093/jalm/jfae074","url":null,"abstract":"","PeriodicalId":46361,"journal":{"name":"Journal of Applied Laboratory Medicine","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142569807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of 2 Sets of Immunoassays Used in Modified 2-Tiered Testing Algorithms for the Diagnosis of Lyme Disease. 比较用于莱姆病诊断的改良双层检测算法中的两套免疫测定。
IF 1.8 Q3 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2024-10-30 DOI: 10.1093/jalm/jfae127
Michael E Walsh, Daniel J Sietsma, Isabella W Martin, Lynn A Brunelle

Background: Since 2019, modified 2-tiered testing (MTTT) algorithms have been available for the diagnosis of Lyme disease. MTTTs replaced the standard algorithms that utilized enzyme immunoassays and immunoblots with sequential enzyme immunoassays that detect different antigens.

Methods: We compared the performance of serological assays from ZEUS Scientific Inc. and DiaSorin Inc. that are used for the diagnosis of Lyme disease. Serological results were compared with clinical information gathered by chart review.

Results: Percent positive agreement (PPA) and percent negative agreement (PNA) for total immunoglobulin G (IgG)/immunoglogulin M (IgM) (n = 120) were 64% (95% confidence interval 54% to 73%) and 100% (87% to 100%), respectively. PPA and PNA for IgG (n = 93) were 91% (80% to 97%) and 66% (52% to 78%), respectively. PPA and PNA for IgM (n = 93) were 75% (62% to 85%) and 95% (82% to 99%), respectively. Fewer positive total IgG/IgM results confirmed positive for either IgG or IgM for ZEUS compared to DiaSorin. Overall MTTT algorithm interpretation was concordant in 58% (55/95) of samples, and concordance improved when the results were limited to IgM in patients with symptom duration <30 days. Treatment with antibiotics was most strongly associated with IgM positivity.

Conclusions: This analysis highlights differences in the performance characteristics between commercially available diagnostic assays for Lyme disease. Our data suggest that the DiaSorin assays would result in fewer positive total IgG/IgM tests, decreasing the required number of confirmatory IgG and IgM tests. This would potentially lead to fewer patients treated with antibiotics.

背景:自 2019 年起,莱姆病的诊断开始采用改良的双层检测(MTTT)算法。MTTT 用检测不同抗原的连续酶免疫测定取代了利用酶免疫测定和免疫印迹的标准算法:我们比较了 ZEUS Scientific 公司和 DiaSorin 公司用于莱姆病诊断的血清检测方法的性能。将血清学结果与通过病历审查收集的临床信息进行比较:总免疫球蛋白 G (IgG)/ 免疫组织蛋白 M (IgM)(n = 120)的阳性一致率 (PPA) 和阴性一致率 (PNA) 分别为 64%(95% 置信区间为 54% 至 73%)和 100%(87% 至 100%)。IgG 的 PPA 和 PNA(n = 93)分别为 91%(80% 至 97%)和 66%(52% 至 78%)。IgM 的 PPA 和 PNA(n = 93)分别为 75%(62% 至 85%)和 95%(82% 至 99%)。与 DiaSorin 相比,ZEUS 确认 IgG 或 IgM 阳性的总 IgG/IgM 阳性结果更少。58%(55/95)的样本的 MTTT 算法解释总体上是一致的,当结果仅限于症状持续时间长的患者的 IgM 时,一致性有所提高:这项分析凸显了市售莱姆病诊断检测方法在性能特征上的差异。我们的数据表明,DiaSorin 检测方法会导致较少的总 IgG/IgM 阳性检测结果,从而减少所需的 IgG 和 IgM 确诊检测次数。这可能会减少接受抗生素治疗的患者人数。
{"title":"Comparison of 2 Sets of Immunoassays Used in Modified 2-Tiered Testing Algorithms for the Diagnosis of Lyme Disease.","authors":"Michael E Walsh, Daniel J Sietsma, Isabella W Martin, Lynn A Brunelle","doi":"10.1093/jalm/jfae127","DOIUrl":"https://doi.org/10.1093/jalm/jfae127","url":null,"abstract":"<p><strong>Background: </strong>Since 2019, modified 2-tiered testing (MTTT) algorithms have been available for the diagnosis of Lyme disease. MTTTs replaced the standard algorithms that utilized enzyme immunoassays and immunoblots with sequential enzyme immunoassays that detect different antigens.</p><p><strong>Methods: </strong>We compared the performance of serological assays from ZEUS Scientific Inc. and DiaSorin Inc. that are used for the diagnosis of Lyme disease. Serological results were compared with clinical information gathered by chart review.</p><p><strong>Results: </strong>Percent positive agreement (PPA) and percent negative agreement (PNA) for total immunoglobulin G (IgG)/immunoglogulin M (IgM) (n = 120) were 64% (95% confidence interval 54% to 73%) and 100% (87% to 100%), respectively. PPA and PNA for IgG (n = 93) were 91% (80% to 97%) and 66% (52% to 78%), respectively. PPA and PNA for IgM (n = 93) were 75% (62% to 85%) and 95% (82% to 99%), respectively. Fewer positive total IgG/IgM results confirmed positive for either IgG or IgM for ZEUS compared to DiaSorin. Overall MTTT algorithm interpretation was concordant in 58% (55/95) of samples, and concordance improved when the results were limited to IgM in patients with symptom duration <30 days. Treatment with antibiotics was most strongly associated with IgM positivity.</p><p><strong>Conclusions: </strong>This analysis highlights differences in the performance characteristics between commercially available diagnostic assays for Lyme disease. Our data suggest that the DiaSorin assays would result in fewer positive total IgG/IgM tests, decreasing the required number of confirmatory IgG and IgM tests. This would potentially lead to fewer patients treated with antibiotics.</p>","PeriodicalId":46361,"journal":{"name":"Journal of Applied Laboratory Medicine","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142548229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Presumptive Identification of Clinically Significant Hemoglobin Variants Hb E, Hb S, Hb D in Hb A1c Capillary Electrophoresis. 在 Hb A1c 毛细管电泳中推定识别具有临床意义的血红蛋白变异体 Hb E、Hb S 和 Hb D。
IF 1.8 Q3 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2024-10-04 DOI: 10.1093/jalm/jfae102
Ankitha K Puthiyaveettil, Glen S Vaz, Sujay R Prasad, Deepalakshmi D Putchen

Background: The quantitation of glycated hemoglobin (Hb A1c) represents an average blood glucose level for a period of 2 to 3 months for diagnosing, monitoring, and managing diabetes mellitus. Unreliable results are reported when hemoglobin (Hb) variants are present in the sample. Patients are advised to use an alternate method due to the presence of the variant Hb and a reflex test to Hb electrophoresis to obtain precise information about the Hb variant. The present study utilizes x axis values from Hb A1c capillary electrophoresis (CE) to identify clinically significant Hb variants Hb E, S, and D.

Methods: Patient samples (n = 60) that showed a variant peak in the Hb A1c test with an x axis value of 190 to 240 were selected for the study. The migration position of the Hb variant (x axis value) and variant percent of the Hb A1c test were compared with the x axis value and variant percent in the Hb electrophoresis test to presumptively identify the variants. The identity of the variants was confirmed using mass spectrometry (MS).

Results: Out of 60 samples, 20 samples were identified as Hb E (x axis 225-227), 20 samples were identified as Hb S (x axis 210-214), and 18 samples were identified as Hb D-Punjab (x axis 200-201). Two variants with an x axis value of 194 were identified as an α variant Hb Q India using MS. There is an overall negative shift of the x axis (-1 to -13 units) and a lower variant percent (-0.2% to -8.7%) in Hb A1c CE when compared with Hb electrophoresis.

Conclusions: The present study highlights the significance of the x axis value and variant percent to identify clinically significant Hb variants in the Hb A1c CE test.

背景:糖化血红蛋白(Hb A1c糖化血红蛋白(Hb A1c)的定量代表 2 至 3 个月的平均血糖水平,用于诊断、监测和管理糖尿病。如果样本中存在血红蛋白(Hb)变异体,则报告的结果不可靠。由于变异血红蛋白的存在,建议患者使用另一种方法,并对血红蛋白电泳进行反射测试,以获得有关变异血红蛋白的准确信息。本研究利用 Hb A1c 毛细管电泳(CE)的 x 轴值来识别具有临床意义的 Hb 变异型 Hb E、S 和 D:研究选取在 Hb A1c 检测中出现变异峰且 x 轴值在 190 至 240 之间的患者样本(n = 60)。将血红蛋白变异体的迁移位置(x 轴值)和血红蛋白 A1c 检测的变异体百分比与血红蛋白电泳检测的 x 轴值和变异体百分比进行比较,以推定变异体。变异体的身份使用质谱法(MS)进行确认:在 60 个样本中,20 个样本被鉴定为 Hb E(x 轴 225-227),20 个样本被鉴定为 Hb S(x 轴 210-214),18 个样本被鉴定为 Hb D-Punjab(x 轴 200-201)。两个 x 轴值为 194 的变异体被 MS 鉴定为 α 变异体 Hb Q India。与血红蛋白电泳相比,Hb A1c CE 的 x 轴总体呈负向移动(-1 至-13 个单位),变异率较低(-0.2% 至-8.7%):本研究强调了在血红蛋白 A1c CE 检测中,X 轴值和变异百分率对识别具有临床意义的血红蛋白变异具有重要意义。
{"title":"Presumptive Identification of Clinically Significant Hemoglobin Variants Hb E, Hb S, Hb D in Hb A1c Capillary Electrophoresis.","authors":"Ankitha K Puthiyaveettil, Glen S Vaz, Sujay R Prasad, Deepalakshmi D Putchen","doi":"10.1093/jalm/jfae102","DOIUrl":"https://doi.org/10.1093/jalm/jfae102","url":null,"abstract":"<p><strong>Background: </strong>The quantitation of glycated hemoglobin (Hb A1c) represents an average blood glucose level for a period of 2 to 3 months for diagnosing, monitoring, and managing diabetes mellitus. Unreliable results are reported when hemoglobin (Hb) variants are present in the sample. Patients are advised to use an alternate method due to the presence of the variant Hb and a reflex test to Hb electrophoresis to obtain precise information about the Hb variant. The present study utilizes x axis values from Hb A1c capillary electrophoresis (CE) to identify clinically significant Hb variants Hb E, S, and D.</p><p><strong>Methods: </strong>Patient samples (n = 60) that showed a variant peak in the Hb A1c test with an x axis value of 190 to 240 were selected for the study. The migration position of the Hb variant (x axis value) and variant percent of the Hb A1c test were compared with the x axis value and variant percent in the Hb electrophoresis test to presumptively identify the variants. The identity of the variants was confirmed using mass spectrometry (MS).</p><p><strong>Results: </strong>Out of 60 samples, 20 samples were identified as Hb E (x axis 225-227), 20 samples were identified as Hb S (x axis 210-214), and 18 samples were identified as Hb D-Punjab (x axis 200-201). Two variants with an x axis value of 194 were identified as an α variant Hb Q India using MS. There is an overall negative shift of the x axis (-1 to -13 units) and a lower variant percent (-0.2% to -8.7%) in Hb A1c CE when compared with Hb electrophoresis.</p><p><strong>Conclusions: </strong>The present study highlights the significance of the x axis value and variant percent to identify clinically significant Hb variants in the Hb A1c CE test.</p>","PeriodicalId":46361,"journal":{"name":"Journal of Applied Laboratory Medicine","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142376164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
FDA's Final Rule on Laboratory-Developed Tests: What Is the Impact on Clinical Pharmacogenomics in the United States? FDA 关于实验室开发检验的最终规定:对美国临床药物基因组学有何影响?
IF 1.8 Q3 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2024-10-04 DOI: 10.1093/jalm/jfae105
Xander M R van Wijk, Gwendolyn A McMillin
{"title":"FDA's Final Rule on Laboratory-Developed Tests: What Is the Impact on Clinical Pharmacogenomics in the United States?","authors":"Xander M R van Wijk, Gwendolyn A McMillin","doi":"10.1093/jalm/jfae105","DOIUrl":"https://doi.org/10.1093/jalm/jfae105","url":null,"abstract":"","PeriodicalId":46361,"journal":{"name":"Journal of Applied Laboratory Medicine","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142376163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Better Prediction of Clinical Outcome with Estimated Glomerular Filtration Rate by CKD-EPI 2021. 用 CKD-EPI 2021 估算肾小球滤过率能更好地预测临床结果。
IF 1.8 Q3 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2024-10-04 DOI: 10.1093/jalm/jfae103
Kwang Seob Lee, Jaehyeok Jang, Hanmil Jang, Hyein Kang, John Hoon Rim, Jong-Baeck Lim

Background: While the real-world impact of estimated glomerular filtration rate (eGFR) equation change on clinical outcome in a longitudinal cohort setting is limited, external valuation of equation performance should be performed in different population cohorts. This study aimed to compare differential impacts of eGFR values, calculated by 5 equations in a Korean patient population, on clinical outcomes.

Methods: This retrospective longitudinal follow-up cohort study analyzed 23 246 participants with standardized creatinine/cystatin C assay-based laboratory results. The primary exposure was baseline eGFR calculated by 5 different equations including the recently developed 2021 race-free Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations. Clinical outcomes including all-cause mortality, renal replacement therapy, and albuminuria were analyzed to estimate the hazard ratio of the eGFR on clinical outcomes.

Results: Among the 5 equations, CKD-EPI 2021 with creatinine and cystatin C (CKD-EPI 2021-CrCys) showed an earlier increase in hazard ratios for all clinical outcomes, while CKD-EPI 2012 with cystatin C showed a higher hazard ratio for all-cause mortality at low eGFR. Replacing CKD-EPI 2012 with CKD-EPI 2021-CrCys, 5.4% of patients with mortality and 3.3% of patients who received renal replacement therapy were reclassified to a lower risk stage.

Conclusions: The 2021 CKD-EPI equations were acceptable in a Korean population, with better predictive power for clinical outcomes when compared to previous equations. The updated race-free factors for eGFR calculation improved identification of patients at risk for clinical outcomes.

背景:尽管在纵向队列设置中,估计肾小球滤过率(eGFR)方程变化对临床结果的实际影响有限,但应在不同人群队列中对方程性能进行外部评估。本研究旨在比较韩国患者群体中通过 5 种方程计算的 eGFR 值对临床结果的不同影响:这项回顾性纵向随访队列研究分析了 23 246 名参与者的标准化肌酐/胱抑素 C 化验结果。主要暴露指标是由 5 种不同方程计算得出的基线 eGFR,包括最近开发的 2021 年无种族差异慢性肾脏病流行病学协作组(CKD-EPI)方程。对包括全因死亡率、肾替代治疗和白蛋白尿在内的临床结果进行了分析,以估计 eGFR 对临床结果的危险比:结果:在 5 个方程中,含肌酐和胱抑素 C 的 CKD-EPI 2021(CKD-EPI 2021-CrCys)显示所有临床结果的危险比增加较早,而含胱抑素 C 的 CKD-EPI 2012 在低 eGFR 时显示全因死亡率的危险比较高。用CKD-EPI 2021-CrCys替代CKD-EPI 2012,5.4%的死亡患者和3.3%的接受肾脏替代治疗的患者被重新分类为较低风险阶段:2021CKD-EPI方程在韩国人群中是可以接受的,与之前的方程相比,对临床结果的预测能力更强。计算 eGFR 的最新无种族因素提高了对临床结果风险患者的识别能力。
{"title":"Better Prediction of Clinical Outcome with Estimated Glomerular Filtration Rate by CKD-EPI 2021.","authors":"Kwang Seob Lee, Jaehyeok Jang, Hanmil Jang, Hyein Kang, John Hoon Rim, Jong-Baeck Lim","doi":"10.1093/jalm/jfae103","DOIUrl":"https://doi.org/10.1093/jalm/jfae103","url":null,"abstract":"<p><strong>Background: </strong>While the real-world impact of estimated glomerular filtration rate (eGFR) equation change on clinical outcome in a longitudinal cohort setting is limited, external valuation of equation performance should be performed in different population cohorts. This study aimed to compare differential impacts of eGFR values, calculated by 5 equations in a Korean patient population, on clinical outcomes.</p><p><strong>Methods: </strong>This retrospective longitudinal follow-up cohort study analyzed 23 246 participants with standardized creatinine/cystatin C assay-based laboratory results. The primary exposure was baseline eGFR calculated by 5 different equations including the recently developed 2021 race-free Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations. Clinical outcomes including all-cause mortality, renal replacement therapy, and albuminuria were analyzed to estimate the hazard ratio of the eGFR on clinical outcomes.</p><p><strong>Results: </strong>Among the 5 equations, CKD-EPI 2021 with creatinine and cystatin C (CKD-EPI 2021-CrCys) showed an earlier increase in hazard ratios for all clinical outcomes, while CKD-EPI 2012 with cystatin C showed a higher hazard ratio for all-cause mortality at low eGFR. Replacing CKD-EPI 2012 with CKD-EPI 2021-CrCys, 5.4% of patients with mortality and 3.3% of patients who received renal replacement therapy were reclassified to a lower risk stage.</p><p><strong>Conclusions: </strong>The 2021 CKD-EPI equations were acceptable in a Korean population, with better predictive power for clinical outcomes when compared to previous equations. The updated race-free factors for eGFR calculation improved identification of patients at risk for clinical outcomes.</p>","PeriodicalId":46361,"journal":{"name":"Journal of Applied Laboratory Medicine","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142376161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinician-Ordered Peripheral Smear Review by a Pathologist Has Low Clinical Utility-A Reference Laboratory Perspective. 临床医生委托病理学家进行外周血涂片复查的临床效用较低--参考实验室的观点。
IF 1.8 Q3 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2024-10-04 DOI: 10.1093/jalm/jfae101
Sanjai Nagendra, Jamie Mongillo, Krystin Dodge, Pratistha Ranjitkar, Betty Burns, Lavonda Allen

Background: Clinician-ordered peripheral smear review by pathologist (CPSR) is commonly ordered and has been recommended for decades. However, the clinical utility of this labor-intensive test in the reference laboratory has not been examined. The objective of this study is to assess hematologic abnormalities identified in CPSR orders and to correlate them with complete blood count (CBC) and laboratory-derived smear review (LDSR) in the reference laboratory.

Methods: Two hundred consecutive CPSRs with corresponding CBCs from April 2023 were run by Sysmex® XN-11 analyzers, and their peripheral smears were examined by a board-certified hematopathologist. Hematologic abnormalities of CPSRs were assessed, and the correlation between CPSR and CBC/LDSR was reviewed.

Results: Nearly one-third of CPSRs (29%) had normal peripheral smears and CBCs. The majority of CPSRs showed nonspecific quantitative abnormalities. When compared against CPSR results, LDSR criteria identified 100% of hematologic abnormalities appropriately. Samples that were not flagged for review by LDSR rules were also reviewed (n = 174) to rule out clinically meaningful false negatives. One minor discrepancy (0.6% of cases) of small platelet aggregates was observed in a patient with a reported platelet count of 139 K/uL that was missed by the LDSR process.

Conclusions: In the reference laboratory setting, our findings demonstrate that LDSR adequately detects significant hematologic abnormalities and, therefore, CPSR should be discontinued.

背景:临床医生要求病理学家进行外周血涂片检查(CPSR)是常见的检查项目,几十年来一直被推荐使用。然而,参考实验室尚未对这一劳动密集型检验的临床实用性进行研究。本研究的目的是评估 CPSR 订单中发现的血液学异常,并将其与参考实验室的全血细胞计数(CBC)和实验室涂片审查(LDSR)相关联:用Sysmex® XN-11分析仪对2023年4月以来的200份连续CPSR和相应的全血细胞计数进行分析,并由一名获得医学会认证的血液病理学家对其外周涂片进行检查。对 CPSR 的血液学异常进行了评估,并审查了 CPSR 与 CBC/LDSR 之间的相关性:近三分之一的 CPSR(29%)外周涂片和全血细胞计数正常。大多数 CPSR 显示非特异性定量异常。与 CPSR 结果相比,LDSR 标准能准确识别 100% 的血液学异常。我们还对 LDSR 规则未标记的样本(n = 174)进行了复查,以排除有临床意义的假阴性。在一名报告血小板计数为 139 K/uL 的患者身上观察到了血小板小聚集的轻微差异(占病例的 0.6%),但 LDSR 流程漏检了这一差异:结论:在参考实验室环境中,我们的研究结果表明 LDSR 能充分检测出重要的血液学异常,因此应停止使用 CPSR。
{"title":"Clinician-Ordered Peripheral Smear Review by a Pathologist Has Low Clinical Utility-A Reference Laboratory Perspective.","authors":"Sanjai Nagendra, Jamie Mongillo, Krystin Dodge, Pratistha Ranjitkar, Betty Burns, Lavonda Allen","doi":"10.1093/jalm/jfae101","DOIUrl":"https://doi.org/10.1093/jalm/jfae101","url":null,"abstract":"<p><strong>Background: </strong>Clinician-ordered peripheral smear review by pathologist (CPSR) is commonly ordered and has been recommended for decades. However, the clinical utility of this labor-intensive test in the reference laboratory has not been examined. The objective of this study is to assess hematologic abnormalities identified in CPSR orders and to correlate them with complete blood count (CBC) and laboratory-derived smear review (LDSR) in the reference laboratory.</p><p><strong>Methods: </strong>Two hundred consecutive CPSRs with corresponding CBCs from April 2023 were run by Sysmex® XN-11 analyzers, and their peripheral smears were examined by a board-certified hematopathologist. Hematologic abnormalities of CPSRs were assessed, and the correlation between CPSR and CBC/LDSR was reviewed.</p><p><strong>Results: </strong>Nearly one-third of CPSRs (29%) had normal peripheral smears and CBCs. The majority of CPSRs showed nonspecific quantitative abnormalities. When compared against CPSR results, LDSR criteria identified 100% of hematologic abnormalities appropriately. Samples that were not flagged for review by LDSR rules were also reviewed (n = 174) to rule out clinically meaningful false negatives. One minor discrepancy (0.6% of cases) of small platelet aggregates was observed in a patient with a reported platelet count of 139 K/uL that was missed by the LDSR process.</p><p><strong>Conclusions: </strong>In the reference laboratory setting, our findings demonstrate that LDSR adequately detects significant hematologic abnormalities and, therefore, CPSR should be discontinued.</p>","PeriodicalId":46361,"journal":{"name":"Journal of Applied Laboratory Medicine","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142376162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Revisiting the Environmental Impact of Inappropriate Clinical Laboratory Testing: A Comprehensive Overview of Sustainability, Economic, and Quality of Care Outcomes. 重新审视不当临床实验室检测对环境的影响:可持续性、经济性和医疗质量结果的综合概述。
IF 1.8 Q3 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2024-10-03 DOI: 10.1093/jalm/jfae087
Luigi Devis, Mélanie Closset, Jonathan Degosserie, Sarah Lessire, Pauline Modrie, Damien Gruson, Emmanuel J Favaloro, Giuseppe Lippi, François Mullier, Emilie Catry

Background: The use of laboratory resources has seen a substantial increase in recent years, driven by automation and emerging technologies. However, inappropriate use of laboratory testing, encompassing both overuse and underuse, poses significant challenges.

Content: This review explores the complex interplay between patient safety, economic, and environmental factors-known as the "triple bottom line" or "3Ps" for people, profit, and planet-associated with inappropriate use of laboratory resources. The first part of the review outlines the impact of inappropriate laboratory testing on patient safety and economic outcomes. Then the review examines the available literature on the environmental impact of laboratory activities. Several practical solutions for mitigating the environmental impact of laboratories are discussed. Finally, this review emphasizes how decreasing unnecessary laboratory testing results in cost savings and environmental benefits, as evidenced by interventional studies, without compromising patient safety.

Summary: The implementation of sustainable practices in laboratories can create a virtuous circle in which reduced testing enhances cost-efficiency, reduces the environmental footprint, and ensures patient safety, thereby benefiting the 3Ps. This review highlights the critical need for appropriate laboratory resource utilization in achieving sustainability in healthcare.

背景:近年来,在自动化和新兴技术的推动下,实验室资源的使用大幅增加。然而,实验室检测的不当使用(包括过度使用和使用不足)带来了巨大挑战:本综述探讨了与实验室资源使用不当有关的患者安全、经济和环境因素(即 "三重底线 "或 "3P",即人、利润和地球)之间复杂的相互作用。综述的第一部分概述了实验室检测不当对患者安全和经济结果的影响。然后,综述研究了有关实验室活动对环境影响的现有文献。综述还讨论了减轻实验室对环境影响的几种切实可行的解决方案。最后,本综述强调了减少不必要的实验室检测如何在不影响患者安全的前提下节约成本并带来环境效益,这一点已得到干预性研究的证实。摘要:在实验室中实施可持续发展的实践可以创造一个良性循环,即减少检测可以提高成本效益、减少环境足迹并确保患者安全,从而使 3Ps 受益。本综述强调了在实现医疗保健的可持续发展过程中合理利用实验室资源的重要性。
{"title":"Revisiting the Environmental Impact of Inappropriate Clinical Laboratory Testing: A Comprehensive Overview of Sustainability, Economic, and Quality of Care Outcomes.","authors":"Luigi Devis, Mélanie Closset, Jonathan Degosserie, Sarah Lessire, Pauline Modrie, Damien Gruson, Emmanuel J Favaloro, Giuseppe Lippi, François Mullier, Emilie Catry","doi":"10.1093/jalm/jfae087","DOIUrl":"10.1093/jalm/jfae087","url":null,"abstract":"<p><strong>Background: </strong>The use of laboratory resources has seen a substantial increase in recent years, driven by automation and emerging technologies. However, inappropriate use of laboratory testing, encompassing both overuse and underuse, poses significant challenges.</p><p><strong>Content: </strong>This review explores the complex interplay between patient safety, economic, and environmental factors-known as the \"triple bottom line\" or \"3Ps\" for people, profit, and planet-associated with inappropriate use of laboratory resources. The first part of the review outlines the impact of inappropriate laboratory testing on patient safety and economic outcomes. Then the review examines the available literature on the environmental impact of laboratory activities. Several practical solutions for mitigating the environmental impact of laboratories are discussed. Finally, this review emphasizes how decreasing unnecessary laboratory testing results in cost savings and environmental benefits, as evidenced by interventional studies, without compromising patient safety.</p><p><strong>Summary: </strong>The implementation of sustainable practices in laboratories can create a virtuous circle in which reduced testing enhances cost-efficiency, reduces the environmental footprint, and ensures patient safety, thereby benefiting the 3Ps. This review highlights the critical need for appropriate laboratory resource utilization in achieving sustainability in healthcare.</p>","PeriodicalId":46361,"journal":{"name":"Journal of Applied Laboratory Medicine","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142366888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
So I Guess I Am a Device? Making the Case for Professional Practice in the Context of the FDA's Final Rule on Laboratory-Developed Tests. 我猜我是设备?在美国食品及药物管理局关于实验室开发测试的最终规则背景下,为专业实践提供依据。
IF 1.8 Q3 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2024-09-19 DOI: 10.1093/jalm/jfae100
Andrew Bryan, Thomas E Grys, Erin H Graf
{"title":"So I Guess I Am a Device? Making the Case for Professional Practice in the Context of the FDA's Final Rule on Laboratory-Developed Tests.","authors":"Andrew Bryan, Thomas E Grys, Erin H Graf","doi":"10.1093/jalm/jfae100","DOIUrl":"https://doi.org/10.1093/jalm/jfae100","url":null,"abstract":"","PeriodicalId":46361,"journal":{"name":"Journal of Applied Laboratory Medicine","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142298308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Considerations for Building a Data Science Culture for the Clinical Laboratory. 为临床实验室建立数据科学文化的注意事项。
IF 1.8 Q3 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2024-09-10 DOI: 10.1093/jalm/jfae093
Benjamin R McFadden
{"title":"Considerations for Building a Data Science Culture for the Clinical Laboratory.","authors":"Benjamin R McFadden","doi":"10.1093/jalm/jfae093","DOIUrl":"https://doi.org/10.1093/jalm/jfae093","url":null,"abstract":"","PeriodicalId":46361,"journal":{"name":"Journal of Applied Laboratory Medicine","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142298307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Applied Laboratory Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1